Thrombomodulin-mediated catabolism of protein C by pleural mesothelial and vascular endothelial cells

Thrombosis and Haemostasis

Volumn 98, Issue 3, 2007, Pages 627-634

  Iakhiaev, Alexei V ^a   Rezaie, Alireza R ^b   Idell, Steven ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endocytosis; Proteases; Protein C S pathway; Thrombin; Thrombomodulin

Indexed keywords

ACTIVATED PROTEIN C; MUTANT PROTEIN; PROTEIN C; RECEPTOR PROTEIN; THROMBIN; THROMBOMODULIN;

ARTICLE; CATABOLISM; CATALYSIS; CELL ADHESION; CONTROLLED STUDY; ENDOCYTOSIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTERNALIZATION; MESOTHELIUM CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; RECEPTOR BINDING; VASCULAR ENDOTHELIUM; WILD TYPE;

ANTIGENS, CD; CELL LINE; CELL MEMBRANE; ENDOCYTOSIS; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; MUTATION; PLEURA; PROTEIN C; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; THROMBIN; THROMBOMODULIN; TIME FACTORS;

EID: 34548671851     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-03-0223     Document Type: Article

References (44)

1. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32 (Suppl 1): 49-60.
2. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272: L197-L202.
3. Grey ST, Tsuchida A, Hau H, et al. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994; 153: 3664-3672.
4. Hirose K, Okajima K, Taoka Y, et al. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 2000; 232: 272-280.
5. Feistritzer C, Sturn DH, Kaneider NC, et al. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol 2003; 112: 375-381.
6. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280: 17286-17293.
7. Zeng W, Matter WF, Yan SB, et al. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med 2004; 32 (5 Suppl): S302-S308.
8. Esmon CT. The endothelial protein C receptor. Curr Opin Hematol 2006; 13: 382-385.
9. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115: 1267-1274.
10. Mosnier LO, Meijers JC, Bourna BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 5-11.
11. Maruyama I, Majerus PW. The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombin. J Biol Chem 1985; 260: 15432-15438.
12. Maruyama I, Majerus PW. Protein C inhibits endocytosis of thrombin-thrombomodulin complexes in A549 lung cancer cells and human umbilical vein endothelial cells. Blood 1987; 69: 1481-1484.
13. Teasdale MS, Bird CH, Bird P. Internalization of the anticoagulant thrombomodulin is constitutive and does not require a signal in the cytoplasmic domain. Immunol Cell Biol 1994; 72: 480-488.
14. Conway EM, Pollefeyt S, Collen D, et al. The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis. Blood 1997; 89: 652-661.
15. Macias WL, Dhainaut JF, Yan SC, et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72: 391-402.
16. Berger H, Jr., Kirstein CG, Orthner CL. Pharmacokinetics of activated protein C in guinea pigs. Blood 1991; 77: 2174-2184.
17. Dhainaut JF, Laterre PF, LaRosa SP, et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 2003; 31: 2291-2301.
18. Li W, Zheng X, Gu J, et al. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost 2005; 3: 1351-1359.
19. Bangalore N, Drohan WN, Orthner CL. High affinity binding sites for activated protein C and protein C on cultured human umbilical vein endothelial cells. Independent of protein S and distinct from known ligands. Thromb Haemost 1994; 72: 465-474.
20. Iakhiaev A, Idell S. Activation and degradation of protein C by primary rabbit pleural mesothelial cells. Lung 2006; 184: 81-88.
21. Rezaie AR, Esmon NL, Esmon CT. The high affinity calcium-binding site involved in protein C activation is outside the first epidermal growth factor homology domain. J Biol Chem 1992; 267: 11701-11704.
22. Wu Q, Tsiang M, Lentz SR, et al. Ligand specificity of human thrombomodulin. Equilibrium binding of human thrombin, meizothrombin, and factor Xa to recombinant thrombomodulin. J Biol Chem 1992; 267: 7083-7088.
23. Pei G, Baker K, Emfinger SM, et al. Expression, isolation, and characterization of an active site (serine 528 - alanine) mutant of recombinant bovine prothrombin. J Biol Chem 1991; 266: 9598-9604.
24. Rezaie AR. Role of exosites 1 and 2 in thrombin reaction with plasminogen activator inhibitor-1 in the absence and presence of cofactors. Biochemistry 1999; 38: 14592-14599.
25. Smirnov MD, Safa O, Regan L, et al. A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. J Biol Chem 1998; 273: 9031-9040.
26. Esmon CT, Gu JM, Xu J, et al. Regulation and functions of the protein C anticoagulant pathway. Haematologica 1999; 84: 363-368.
27. Kisiel W, Davie E. Protein C. Methods Enzymol 1981; 80: 320-332.
28. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249-2252.
29. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-26491.
30. Fukudome Y, Kurosawa S, Stearns-Kurosawa DJ, et al. The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem 1996; 271: 17491-17498.
31. Ye X, Fukudome K, Tsuneyoshi N, et al. The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries. Biochem Biophys Res Commun 1999; 259: 671-677.
32. Ghosh S, Pendurthi UR, Esmon CT, et al. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007; prepub online.
33. Nishioka J, Ido M, Hayashi T, et al. The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va. Thromb Haemost 1996; 75: 275-282.
34. Lu G, Chhum S, Krishnaswamy S. The affinity of protein C for the thrombin.thrombomodulin complex is determined in a primary way by active site-dependent interactions. J Biol Chem 2005; 280: 15471-15478.
35. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, et al. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93: 10212-10216.
36. Fukudome K, Esmon CT. Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR). The structural and functional conservation in human, bovine, and murine EPCR. J Biol Chem 1995; 270: 5571-5577.
37. Regan LM, Mollica JS, Rezaie AR, et al. The interaction between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C. J Biol Chem 1997; 272: 26279-26284.
38. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-1882.
39. Riewald M, Petrovan RJ, Donner A, et al. Activated protein C signals through the thrombin receptor PAR1 in endothelial cells. J Endotoxin Res 2003; 9: 317-321.
40. Xie J, Qian L, Wang Y, et al. Role ofthe microtubule cytoskeleton in traffic of EGF through the lacrimal acinar cell endomembrane network. Exp Eye Res 2004; 78: 1093-1106.
41. Conway EM, Nowakowski B, Steiner-Mosonyi M. Thrombomodulin lacking the cytoplasmic domain efficiently internalizes thrombin via nonclathrin-coated, pit-mediated endocytosis. J Cell Physiol 1994; 158: 285-298.
42. Brisson C, Archipoff G, Hartmann ML, et al. Anti-bodies to thrombomodulin induce receptor-mediated endocytosis in human saphenous vein endothelial cells. Thromb Haemost 1992; 68: 737-743.
43. Dhainaut JF, Marin N, Mignon A, et al. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 2001; 29 (7 Suppl): S42-S47.
44. Li W, Zheng X, Gu JM, et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood 2005; 106: 2716-2722.